ReviewCells2022
The DREADDful Hurdles and Opportunities of the Chronic Chemogenetic Toolbox.
Review in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Next-generation chemogenetic inhibition using a brain-permeant non-prescription agent.Signal transduction and targeted therapy · 2026Article
- The mitigation of activity-based anorexia by obese adipose tissue transplant is abolished by neonatal AgRP neuron ablation.Translational psychiatry · 2026Article
- CeA-projecting VTA neurons contribute to alcohol withdrawal-induced anxiety-like behavior in male and female rats.Alcohol (Fayetteville, N.Y.) · 2026Article
- Protocol to study inter-tissue communication between the hypothalamus and white adipose tissue and lifespan using a chemogenetic approach in aged mice.STAR protocols · 2025Article
- Review
- Adolescent Cerebellar Nuclei Manipulation Alters Reversal Learning and Perineuronal Net Intensity Independently in Male and Female Mice.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025Article
- Chronic chemogenetic slow-wave-sleep enhancement in mice.bioRxiv : the preprint server for biology · 2025Article
- Delineation of the trigeminal-lateral parabrachial-central amygdala tract in humans.Imaging neuroscience (Cambridge, Mass.) · 2025Article
- Parabrachial calcitonin gene-related peptide neurons sex-specifically modulate behavior in anxiety assays during alcohol withdrawal.Frontiers in pharmacology · 2025Article
- Strength of activation and temporal dynamics of bioluminescent-optogenetics in response to systemic injections of the luciferin.NeuroImage · 2024Article
- Feedforward inhibition of stress by brainstem neuropeptide Y neurons.Nature communications · 2024Article
- Neurosecretory Protein GM-Expressing Neurons Participate in Lipid Storage and Inflammation in Newly Developed Cre Driver Male Mice.Biomedicines · 2023Article
- Advanced neurobiological tools to interrogate metabolism.Nature reviews. Endocrinology · 2023Review
- High dose administration of DREADD agonist JHU37160 produces increases in anxiety-like behavior in male rats.Behavioural brain research · 2023Article
- The Sympathetic Innervation of Adipose Tissues: Regulation, Functions, and Plasticity.Comprehensive Physiology · 2023Article
- Cardiovascular Brain Circuits.Circulation research · 2023Review
- Chemogenetic and Optogenetic Manipulations of Microglia in Chronic Pain.Neuroscience bulletin · 2023Review
- Comparative assessment of the effects of DREADDs and endogenously expressed GPCRs in hippocampal astrocytes on synaptic activity and memory.Frontiers in cellular neuroscience · 2023Review
- DREADD-mediated amygdala activation is sufficient to induce anxiety-like responses in young nonhuman primates.Current research in neurobiology · 2023Article
- The dawn has come for new therapeutics to treat atherosclerosis: Targeting neuroimmune cardiovascular interfaces in artery brain circuits.Clinical and translational medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The chronic character of chemogenetics has been put forward as one of the assets of the technique, particularly in comparison to optogenetics. Yet, the vast majority of chemogenetic studies have focused on acute applications, while repeated, long-term neuromodulation has only been booming in the past few years. Unfortunately, together with the rising number of studies, various hurdles have also been uncovered, especially in relation to its chronic application. It becomes increasingly clear that chronic neuromodulation warrants caution and that the effects of acute neuromodulation cannot be extrapolated towards chronic experiments. Deciphering the underlying cellular and molecular causes of these discrepancies could truly unlock the chronic chemogenetic toolbox and possibly even pave the way for chemogenetics towards clinical application. Indeed, we are only scratching the surface of what is possible with chemogenetic research. For example, most investigations are concentrated on behavioral read-outs, whereas dissecting the underlying molecular signature after (chronic) neuromodulation could reveal novel insights in terms of basic neuroscience and deregulated neural circuits. In this review, we highlight the hurdles associated with the use of chemogenetic experiments, as well as the unexplored research questions for which chemogenetics offers the ideal research platform, with a particular focus on its long-term application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.